Subscribe
Today
Financial
Technology
Cyclical
Defensive
Healthcare
Energy
Industrials
Real Estate
Materials
Viewpoints
All Access Articles |
IBRX
ImmunityBio's Anktiva Shows 71% Complete Response Rate
| 2024-11-19 |
BIOTECHNOLOGY
Analyzing the Fundamental Performance of IBRX
| 2024-04-27 |
BIOTECHNOLOGY
